PhaseBio Pharmaceuticals Income from Continuous Operations

Income from Continuous Operations of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Income from Continuous Operations growth rates and interactive chart.


Highlights and Quick Summary

  • Income from Continuous Operations for the quarter ending June 30, 2022 was $-16.7 Million (a 49.58% increase compared to previous quarter)
  • Year-over-year quarterly Income from Continuous Operations decreased by -47.8%
  • Annual Income from Continuous Operations for 2021 was $-131 Million (a 32.98% increase from previous year)
  • Annual Income from Continuous Operations for 2020 was $-98.6 Million (a 151.14% increase from previous year)
  • Annual Income from Continuous Operations for 2019 was $-39.2 Million (a 64.59% increase from previous year)
  • Twelve month Income from Continuous Operations ending June 30, 2022 was $-103 Million (a -10.46% decrease compared to previous quarter)
  • Twelve month trailing Income from Continuous Operations decreased by -13.09% year-over-year
Trailing Income from Continuous Operations for the last four month:
30 Jun '22 31 Mar '22 31 Dec '21 30 Sep '21
$-103 Million $-115 Million $-131 Million $-118 Million
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Income from Continuous Operations of PhaseBio Pharmaceuticals

Most recent Income from Continuous Operationsof PHAS including historical data for past 10 years.

Interactive Chart of Income from Continuous Operations of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Income from Continuous Operations for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-16.67 $-11.14
2021 $-43.11 $-31.92 $-28.68 $-27.36 $-131.07
2020 $-30.38 $-25.14 $-28.14 $-14.91 $-98.57
2019 $-11.33 $-11.39 $-9.23 $-7.29 $-39.25
2018 $-4.87 $-7.9 $-6.67 $-4.4 $-23.85
2017 $-2.56 $-10.25

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology